Previous studies have suggested that RAS-acting agents may reduce the risk of cognitive decline by favourably modulating the renin-angiotensin system, which involves mitigating inflammation, vascular dysfunction, and insulin resistance [28, 29]. Here, REN is linked to Insulin resistance.